last
decad
outbreak
emerg
infecti
diseas
sever
acut
respiratori
syndrom
sar
avianswin
influenza
impact
human
diseas
control
system
reconsid
rais
demand
develop
nextgener
vaccin
vaccin
effect
intervent
infecti
diseas
mani
vaccin
howev
effect
prevent
onset
aggrav
symptom
less
effect
prevent
infect
particular
respiratori
infect
influenza
reason
major
administr
rout
convent
vaccin
includ
subcutan
sc
intramuscular
im
one
induc
neutral
igg
antibodi
blood
mucos
iga
antibodi
effect
prevent
infect
addit
efficaci
igg
antibodi
mutat
virus
limit
highli
restrict
crossprotect
capabl
convers
iga
antibodi
mucosa
show
wide
crossprotect
block
infect
immun
deliv
mucosa
iga
antibodi
induc
mucos
surfac
throughout
bodi
mucos
vaccin
induc
immun
system
mucos
compart
enhanc
antigenspecif
mucos
immun
clear
goal
nextgener
vaccin
mucos
particularli
nasal
vaccin
promis
effect
prevent
infect
via
respiratori
tract
nasal
vaccin
addit
benefit
improv
patient
complianc
greater
clinic
conveni
one
signific
drawback
mucos
vaccin
gener
induc
strong
enough
immun
respons
recent
componentsplit
vaccin
avoid
mani
neg
patient
reaction
tend
less
immunogen
even
case
intraven
iv
im
administr
gener
children
elderli
tend
respond
less
vaccin
may
lower
prevent
power
popul
adjuv
must
administ
simultan
vaccin
order
enhanc
vaccinespecif
immun
respons
among
adjuv
alum
salt
use
neither
suitabl
vaccin
alway
capabl
elicit
desir
immun
respons
type
adjuv
develop
liposom
emuls
combin
develop
safe
effect
suitabl
adjuv
variou
vaccin
expect
meet
new
type
vaccin
tumor
necrosi
major
proinflammatori
cytokin
primarili
produc
cell
macrophag
origin
found
potent
antitumor
factor
known
play
integr
role
host
defens
includ
innat
adapt
immun
activ
dendrit
cell
dc
matur
subsequ
cell
activ
well
contribut
inflammatori
respons
interestingli
recent
shown
exert
adjuv
activ
pathogen
infect
although
molecul
attract
interest
mani
investig
attempt
develop
vaccin
adjuv
success
result
report
probabl
caus
unfavor
biolog
reaction
administ
system
rapidli
degrad
mucos
surfac
deliv
mucos
overcom
investig
attempt
gener
proteaseresist
mutant
molecul
order
establish
safer
effect
way
administ
bioactiv
substanc
drugdeliveri
system
dd
nanoparticl
made
biocompat
polym
attract
grow
interest
recent
one
materi
cholesteryl
pullulan
chp
polysaccharid
pullulan
chemic
modifi
cholesteryl
group
form
selfassembl
nanoparticl
aqueou
solut
entrap
variou
molecul
intern
space
hydrophob
interact
furthermor
protect
entrap
molecul
mechanicalchem
enzymat
attack
outsid
particl
act
superior
carrier
deliveri
achiev
slow
releas
encapsul
materi
shown
chp
nanoparticl
effici
transfer
antigenpres
cell
macrophag
andor
dc
elicit
strong
immun
respons
chp
vigor
investig
establish
novel
vaccin
therapi
sever
type
cancer
report
encapsul
human
chp
result
tnfchp
nanoparticl
examin
potenti
nanoparticl
nasal
vaccin
adjuv
protect
lethal
influenza
infect
mous
model
conduct
mechanist
analys
human
prepar
previous
describ
briefli
protein
produc
human
b
cell
lymphoblastoid
cell
line
stimul
hemagglutin
viru
japan
hvj
highli
purifi
seri
chromatographi
column
includ
specif
monoclon
antibodi
column
endotoxin
level
purifi
determin
less
pgmg
protein
chp
partial
glucos
unit
modifi
polysaccharid
pullulan
cholesteryl
residu
purebright
purchas
nof
co
tokyo
japan
influenza
viru
apuerto
strain
provid
dr
ayato
takada
research
center
zoonosi
control
hokkaido
univers
japan
influenza
viru
ha
vaccin
ivv
seiken
purchas
denka
seiken
co
ltd
tokyo
japan
split
trival
vaccin
season
influenza
consist
inactiv
ha
antigen
two
hundr
fifti
mgml
chp
mix
steril
filtrat
incub
incub
chp
encapsul
molecul
form
nanoparticl
unencapsul
remov
sizeexclus
chromatographi
column
ge
healthcar
fairfield
ct
size
particl
determin
dynam
light
scatter
dl
zetas
nano
zs
malvern
instrument
ltd
malvern
uk
estim
amount
encapsul
nanoparticl
treat
mgml
sigmaaldrich
co
saint
loui
mo
h
disrupt
particl
structur
releas
describ
amount
determin
enzymelink
immunosorb
assay
elisa
system
describ
amount
human
determin
elisa
system
establish
inhous
hayashibara
co
ltd
briefli
antihuman
mous
antibodi
immobil
plate
nuncimmuno
plate
nunc
rochest
ny
incub
sampl
hors
radish
peroxidas
hrpo
label
antihuman
mous
antibodi
ad
well
ophenylenediamin
substrat
hrpo
ad
detect
immun
complex
absorb
nm
measur
purifi
human
protein
use
standard
elisa
system
recogn
activ
trimer
molecul
detect
limit
ngml
balbc
mice
femal
obtain
charl
river
laboratori
japan
inc
yokohama
japan
use
week
quarantin
acclim
studi
approv
laboratori
anim
care
committe
hayashibara
co
ltd
anim
experi
procedur
accord
guidelin
care
use
laboratori
anim
hayashibara
co
ltd
mice
anesthet
sevofluran
antigen
andor
adjuv
prepar
nasal
caviti
administ
nasal
indic
time
blood
nasal
wash
obtain
mice
briefli
anim
anesthet
ether
blood
taken
abdomin
aorta
heparin
syring
jaw
incis
bilater
nasal
caviti
vicin
root
tongu
expos
nasal
caviti
wash
salin
wash
recov
blood
nasal
wash
centrifug
rpm
min
store
examin
thorough
wash
nasal
caviti
salin
upper
palat
remov
nalt
isol
microscop
nalt
cell
suspend
strainer
bd
franklin
lake
nj
recov
centrifug
nasal
passag
cell
prepar
report
briefli
nasal
passag
cell
obtain
chip
wall
nasal
caviti
minc
dispers
collagenas
roch
basel
switzerland
cell
suspend
strainer
separ
biphas
centrifug
percol
ge
healthcar
rpm
min
cell
boundari
phase
collect
wash
rpmi
medium
antibodi
respons
plasma
nasal
wash
immun
anim
determin
use
elisa
ivv
immobil
micropl
respect
antibodi
plasma
nasal
wash
examin
indic
hrpolabel
rat
antimous
life
technolog
co
carlsbad
ca
hrpolabel
goat
antimous
iga
southern
biotechnolog
associ
inc
birmingham
al
iga
use
ophenylenediamin
absorb
measur
nm
specif
antibodi
respons
examin
detect
neutral
activ
plasma
influenza
type
type
type
b
plasma
mice
immun
ivv
tnfchp
nanoparticl
subject
hemagglutin
inhibit
hi
assay
perform
falco
biosystem
ltd
kyoto
japan
result
express
geometr
mean
titer
gmt
sixtyeight
hour
nasal
immun
nalt
cell
prepar
mice
describ
block
fcr
blocker
milteni
biotec
bergisch
gladbach
germani
cell
stain
fluorescein
isothiocyan
fitc
label
antimous
antibodi
fitclabel
antimous
antibodi
fitclabel
antimous
antibodi
milteni
biotec
subject
flow
cytometri
fcm
analysi
use
flow
cytomet
gallio
beckman
coulter
brea
ca
ovalbumin
ova
sigmaaldrich
co
label
alexa
use
alexa
fluor
label
kit
life
technolog
co
carlsbad
ca
accord
manufactur
instruct
result
alexalabel
ova
use
indic
antigen
nasal
administr
mice
without
tnfchp
nanoparticl
adjuv
six
h
administr
label
ova
nalt
cell
nasal
passag
cell
prepar
mice
describ
block
fcr
blocker
milteni
biotec
bergisch
gladbach
germani
stain
phycoerythrin
pe
label
antimous
antibodi
ebiosci
san
diego
ca
subject
fcm
analysi
result
examin
flow
cytometri
analysi
softwar
gatelog
inivai
technolog
pti
ltd
menton
victoria
australia
antigen
uptak
estim
floresc
intens
alexa
intens
cell
activ
dendrit
cell
dc
total
rna
prepar
nalt
cell
pool
mice
approxim
cell
use
rneasi
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
confirm
puriti
qualiti
rna
cdna
synthes
use
first
strand
kit
sa
bioscienc
co
frederick
md
express
variou
cytokin
factor
relat
immun
respons
examin
mous
innat
adapt
immun
respons
pcr
array
sa
bioscienc
co
roch
lytecycl
roch
accord
instruct
analyz
express
factor
relat
innat
adapt
immun
respons
primer
set
cxc
ligand
tolllik
receptor
lipopolysaccharid
lp
bind
protein
lactotransferrin
tabl
prepar
sigmaaldrich
co
express
level
normal
level
gapdh
quantifi
quantit
pcr
roch
lytecycl
roch
nalt
cell
pool
mice
cultur
micropl
feeder
splenocyt
treat
mitomycin
min
presenc
ivv
antigen
cell
prolifer
examin
alamarblu
life
technolog
co
repres
differ
fluoresc
intens
case
without
ivv
cultur
supernat
recov
h
cytokineproduc
cell
examin
use
elispot
plu
mous
elispot
plu
mous
mabtech
ab
nacka
strand
sweden
kit
result
repres
differ
number
cytokineposit
cell
case
without
ivv
stimul
mice
anesthet
sevofluran
administ
nasal
prepar
per
nasal
caviti
week
week
n
sampl
prepar
mix
ivv
nanoparticl
prepar
cholera
toxin
bsubunit
ctb
sigmaaldrich
co
use
seven
final
immun
mice
challeng
influenza
viru
puerto
nasal
dosag
viru
correspond
mice
viruschalleng
mice
monitor
daili
bodi
weight
sign
morbid
mice
moribund
lost
bodi
weight
consid
reach
experiment
endpoint
human
euthan
anesthet
pentobarbit
refer
oecd
guidelin
test
chemic
preliminari
safeti
studi
perform
mice
head
sex
group
administ
nasal
tnfchp
nanoparticl
prepar
combin
ivv
week
either
four
time
acut
repeat
toxic
respect
addit
anim
went
week
repeat
administr
follow
week
cessat
examin
gener
symptom
examin
day
bodi
weight
food
consumpt
record
weekli
bodi
temperatur
record
h
administr
item
ophthalm
examin
hematolog
blood
biochemistri
urinalysi
blood
antibodi
titer
autopsi
find
histopatholog
analys
major
organ
inspect
acut
toxic
repeat
toxic
blood
biochemistri
analys
perform
orient
yeast
co
ltd
tokyo
japan
furthermor
nasal
mucos
tissu
administr
site
examin
histopatholog
valu
express
mean
valu
sd
sem
student
ttest
use
comparison
group
oneway
anova
tukey
test
use
determin
signific
differ
multipl
comparison
differ
probabl
valu
p
consid
signific
chp
encapsul
activ
trimer
form
stabl
nanoparticl
base
preliminari
experi
optim
condit
prepar
nanoparticl
incub
mgml
chp
encapsul
process
temperatur
timedepend
hardli
occur
condit
condit
typic
encapsul
chp
complex
result
nanoparticl
rel
uniform
peak
averag
size
particl
nm
nm
base
dl
result
differ
blank
chp
particl
nm
nm
respect
figur
stoichiometr
analys
show
tnfchp
nanoparticl
consist
activ
trimer
ca
kda
chp
tetramer
complex
ca
kda
stabil
nanoparticl
dulbecco
phosphat
buffer
dpb
evalu
estim
amount
encapsul
use
disrupt
chp
complex
releas
insid
particl
result
show
nanoparticl
retain
integr
kept
molecul
activ
insid
complex
aqueou
solut
room
temperatur
least
tabl
integr
particl
also
maintain
even
five
cycl
freez
thaw
data
shown
result
show
tnfchp
nanoparticl
remark
stabl
howev
upon
contact
high
concentr
dissolv
protein
albumin
serum
nanoparticl
prone
releas
encapsul
rapidli
probabl
replac
protein
outsid
report
data
shown
although
known
immuneenhanc
activ
sever
unfavor
effect
hamper
practic
use
thought
delay
releas
tnfchp
nanoparticl
might
promot
benefici
effect
vaccin
adjuv
avoid
harm
event
examin
adjuv
activ
tnfchp
nanoparticl
exampl
enhanc
induct
antigenspecif
antibodi
mice
particularli
case
nasal
administr
result
show
nasal
administ
tnfchp
nanoparticl
combin
ivv
induc
signific
level
iga
nasal
wash
well
blood
plasma
figur
b
result
compar
posit
control
ctb
model
adjuv
howev
ivv
chp
alon
without
free
fail
induc
signific
level
antibodi
compar
ivv
alon
tnfchp
nanoparticl
alon
induc
measur
antibodi
respons
ivv
also
examin
antigen
specif
hemagglutinin
ha
specif
hemagglutin
inhibit
hi
assay
ivv
use
consist
differ
type
influenza
viru
tnfchp
nanoparticl
ivv
induc
signific
hi
activ
type
ha
use
b
figur
c
effect
compar
ctb
antigenspecif
cell
respons
anim
examin
use
splenocyt
ivvspecif
prolifer
tnfchp
nanoparticl
group
compar
ctb
figur
regard
cytokin
product
measur
elispot
ivv
alon
increas
cell
either
adjuv
alon
tnfchp
nanoparticl
ctb
suppress
product
instead
cell
increas
nasal
administr
vaccin
adjuv
combin
figur
b
tnfchp
nanoparticl
enhanc
host
immun
effect
seem
stronger
ctb
vaccin
adjuv
posit
control
directli
address
stimulatori
effect
tnfchp
nanoparticl
protect
immun
vaccin
adjuv
carri
experiment
lethal
influenza
viru
challeng
immun
mice
mice
nasal
immun
ivv
combin
without
tnfchp
nanoparticl
correspond
week
time
mice
challeng
influenza
viru
strain
pfumous
final
immun
mice
receiv
ivv
die
challeng
almost
without
ivv
immun
tnfchp
nanoparticl
without
ivv
delay
onset
death
littl
eventu
anim
die
contrari
combin
administr
ivv
tnfchp
nanoparticl
show
highli
protect
effect
mice
anim
surviv
effect
compar
ctb
adjuv
free
tnf
also
show
somewhat
protect
effect
interestingli
chp
without
provid
certain
level
protect
observ
surviv
figur
surviv
anim
immun
ivv
tnfchp
nanoparticl
immunolog
memori
includ
plasma
iga
nasalvagin
wash
memori
maintain
mice
respond
boost
challeng
ivv
data
shown
data
indic
nanoparticl
induc
system
immun
longliv
memori
overal
data
demonstr
tnfchp
nanoparticl
effect
vaccin
adjuv
nasal
deliv
ivv
focus
nasal
rout
vaccin
examin
immun
cell
nasal
tissu
immun
sixtyeight
h
nasal
immun
time
nalt
cell
prepar
mice
express
surfac
marker
marker
dc
activ
marker
b
cell
examin
flow
cytometri
ratio
cell
popul
salin
ivv
ivv
tnfchp
nanoparticl
respect
ratio
popul
salin
ivv
ivv
tnfchp
nanoparticl
respect
figur
even
though
degre
rel
small
extent
ivv
vaccin
without
tnfchp
nanoparticl
activ
dc
b
cell
effect
tnfchp
nanoparticl
promin
find
mechan
nasal
administ
tnfchp
nanoparticl
exert
immuneenhanc
activ
next
focus
earli
immun
respons
nasal
mucos
tissu
experi
use
alexa
ovalbumin
ova
model
antigen
assess
antigen
uptak
dc
nalt
nasal
passag
cell
h
immun
flow
cytometri
result
analyz
gatelog
softwar
express
fluoresc
valu
alexa
cell
immun
mice
ova
combin
tnfchp
nanoparticl
activ
antigen
uptak
nalt
nasal
passag
dc
nasal
passag
dc
respond
particularli
well
tnfchp
nanoparticl
seem
stimul
dc
nasal
mucos
immun
tissu
figur
understand
nasal
tissu
activ
caus
tnfchp
nanoparticl
soon
immun
conduct
gene
express
profil
nalt
cell
h
nasal
immun
ivv
antigen
combin
without
nanoparticl
scatter
analys
gene
express
inflammationrel
molecul
exampl
trigger
receptor
express
myeloid
cell
tlr
famili
found
significantli
upregul
data
shown
analys
inflammatori
signal
molecul
induc
tnfchp
nanoparticl
focus
molecul
list
tabl
perform
quantit
pcr
analys
h
activ
nalt
cell
although
chp
show
signific
immuneenhanc
activ
inflammatori
marker
enhanc
adjuv
includ
tnfchp
nanoparticl
free
tnf
ctb
among
molecul
test
signific
increas
express
lp
bind
protein
found
degre
enhanc
vari
gene
gene
particular
express
intens
enhanc
gene
free
tnf
result
strong
earli
increas
express
enhanc
tend
greater
h
h
figur
express
profil
tnfchp
nanoparticl
similar
free
tnf
although
magnitud
great
although
express
promin
ctb
use
adjuv
respons
much
lower
tnfchp
nanoparticl
gener
symptom
behavior
anomali
either
male
femal
anim
correl
tnfchp
nanoparticl
ivv
treatment
studi
period
ophthalm
examin
test
materialrel
ocular
find
observ
bodi
weight
bodi
temperatur
sex
treatment
statist
differ
among
treatment
group
data
shown
hematolog
evalu
also
perform
end
studi
differ
paramet
white
blood
cell
red
blood
cell
hematocrit
lymphocyt
neutrophil
eosinophil
basophil
monocyt
consid
due
administr
tnfchp
nanoparticl
ivv
blood
biochemistri
total
protein
albumin
urea
nitrogen
creatinin
na
k
inorgan
phosphat
aspart
aminotransferas
ast
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
amylas
ami
transpeptidas
total
cholesterol
triglycerid
hdlcholesterol
total
bilirubin
glucos
examin
differ
found
studi
fell
within
histor
control
valu
rang
consid
test
materialrel
data
shown
urobilinogen
bilirubin
keton
bodi
glucos
protein
ph
specif
graviti
nitrit
salt
leucocyt
examin
studi
period
tnfchp
nanoparticl
ivvrel
chang
observ
data
shown
antiivv
blood
examin
administr
tnfchp
nanoparticl
ivv
detect
antibodi
induc
singl
administr
second
administr
howev
antibodi
induc
tnfchp
nanoparticl
combin
ivv
titer
maintain
even
week
cessat
period
effect
tnfchp
nanoparticl
vaccin
adjuv
confirm
experi
femal
tend
respond
immun
higher
tabl
gross
patholog
anim
examin
end
studi
gross
patholog
find
none
consid
tnfchp
nanoparticl
ivvrel
major
organ
brain
heart
lung
kidney
liver
ovari
testi
spleen
adren
thymu
measur
end
studi
anim
organ
weight
chang
note
test
materialrel
data
shown
histopatholog
tissu
anim
group
examin
histopatholog
find
none
consid
tnfchp
nanoparticl
ivvrel
nasal
administr
possibl
harm
effect
central
nervou
system
concern
howev
abnorm
brain
especi
olfactori
bulb
note
anim
histolog
examin
hand
influenc
observ
nasal
mucos
tissu
first
singl
administr
specimen
show
effect
case
repeat
administr
ivv
affect
mucos
tissu
greatli
except
slight
infus
probabl
caus
repeat
stimul
hand
tnfchp
nanoparticl
combin
ivv
induc
slighttomoder
infus
infiltr
inflammatori
cell
lymphocyt
neutrophil
eosinophil
mast
cell
find
howev
diminish
trace
proport
week
cessat
period
excess
inflammatori
symptom
format
edema
fibrosi
note
figur
summari
signific
chang
due
administr
tnfchp
nanoparticl
ivv
observ
acut
toxic
studi
repeat
toxic
studi
slighttomoder
infus
inflammatori
cell
infiltr
observ
nasal
mucosa
administr
site
respons
howev
seem
revers
overal
immunotox
detect
although
evalu
requir
result
demonstr
toxic
tnfchp
nanoparticl
rel
low
studi
attempt
test
new
adjuv
prepar
potent
immunoregulatori
cytokin
dd
materi
human
success
incorpor
chp
complex
form
stabl
nanoparticl
prepar
process
effici
result
nanoparticl
rel
uniform
figur
robust
nanoparticl
excel
storag
stabil
week
room
temperatur
tabl
mani
medic
formul
especi
biolog
one
requir
storag
low
temperatur
freez
contrari
tnfchp
nanoparticl
could
store
solut
without
refriger
formul
offer
improv
conveni
handl
transport
known
interact
cholesteryl
group
disrupt
chp
complex
releas
substanc
insid
particl
case
tnfchp
nanoparticl
amount
requir
disrupt
particl
structur
approxim
mgml
much
higher
mgml
report
case
nanoparticl
suggest
affin
chp
much
stronger
chp
seem
trimer
fit
well
inner
space
chp
complex
molecular
interact
chp
topic
studi
group
examin
immuneenhanc
activ
tnfchp
nanoparticl
administ
nasal
administ
ivv
tnfchp
nanoparticl
induc
high
level
iga
nasal
wash
well
blood
plasma
figur
b
furthermor
antigenspecif
antibodi
respons
induc
influenza
type
b
well
type
type
consist
ivv
use
figur
c
suggest
nasal
vaccin
cover
broad
rang
antigen
report
effect
compar
ctb
recogn
power
vaccin
adjuv
experiment
set
data
indic
tnfchp
nanoparticl
administ
nasal
induc
mucos
also
system
immun
significantli
effici
stimulatori
effect
seen
antigen
hepat
viru
type
vaccin
diphtheria
toxoid
data
shown
data
suggest
tnfchp
nanoparticl
potenti
vaccin
adjuv
broad
rang
applic
tnfchp
nanoparticl
elicit
immun
activ
compar
ctb
figur
elispot
analysi
indic
nanoparticl
decreas
cell
increas
cell
figur
b
data
suggest
nasal
administ
adjuv
shift
balanc
state
confirm
previou
result
mutant
effect
tnfchp
nanoparticl
seem
stronger
ctb
directli
address
use
tnfchp
nanoparticl
vaccin
adjuv
protect
immun
employ
lethal
influenza
challeng
mous
model
mice
immun
influenza
viru
follow
challeng
antigen
distinct
influenza
viru
apuerto
nasal
administ
tnfchp
nanoparticl
induc
protect
immun
spite
distinct
antigen
suggest
potenti
induc
broad
crossprotect
figur
muraoka
et
al
propos
chpbase
nanoparticl
preferenti
deliv
antigen
antigenpres
cell
lymph
node
potenti
effect
immun
respons
might
reason
tnfchp
nanoparticl
induc
excel
protect
immun
howev
report
chp
show
adjuv
effect
context
tumor
vaccin
interestingli
chp
without
show
certain
level
efficaci
studi
reason
discrep
result
clear
unlik
replac
vivo
ivv
antigen
form
ivvchp
nanoparticl
would
preferenti
deliv
vaccin
antigen
lymph
node
given
short
time
frame
oyewumi
et
al
report
particl
size
critic
adjuv
activ
dl
analys
show
differ
particl
size
tnfchp
nanoparticl
empti
chp
particl
figur
size
differ
explain
discrep
either
protect
extern
pathogen
influenza
viru
intern
antigen
tumor
antigen
might
reli
differ
mechan
tnfchp
nanoparticl
enhanc
iga
respons
site
applic
ie
nasal
wash
also
distant
mucos
site
includ
vagin
salivari
gland
data
shown
iga
antibodi
elicit
mucosa
vital
import
natur
rout
infect
influenza
via
respiratori
mucosa
henc
local
mucos
protect
pharyng
carriag
like
decis
prevent
diseas
convent
parenter
vaccin
abl
stimul
mucos
immun
respons
thu
restrict
efficaci
infect
mucos
surfac
respiratori
tract
nasal
vaccineadjuv
formul
consist
ivv
tnfchp
nanoparticl
effect
induc
system
mucos
protect
immun
antibodi
becam
detect
second
third
vaccin
reach
plateau
level
thereaft
mice
vaccin
tnfchp
nanoparticl
data
shown
also
nanoparticl
maintain
immun
respons
long
period
time
least
data
shown
data
indic
nanoparticl
induc
longliv
immun
memori
critic
featur
success
vaccin
adjuv
mucos
surfac
known
abund
b
cell
cell
plasma
dc
cell
repeat
immun
anim
activ
dc
b
cell
seem
enhanc
nalt
tissu
tnfchp
nanoparticl
despit
small
extent
figur
uptak
antigen
mucos
tissu
essenti
induct
immun
respons
therefor
examin
antigen
uptak
naltresid
nasal
passag
dc
induct
site
common
mucos
immun
system
cmi
tnfchp
nanoparticl
seem
stimul
nalt
nasal
passag
dc
particular
latter
intens
figur
also
tnfchp
nanoparticl
enhanc
express
dc
b
cell
activ
marker
bone
marrowderiv
immatur
dc
prepar
data
shown
consid
rel
larg
volum
nasal
administr
studi
possibl
tnfchp
nanoparticl
affect
immun
cell
lower
respiratori
tract
well
nasal
mucosa
consid
plan
explor
possibl
futur
studi
vaccin
adjuv
trigger
innat
immun
system
enhanc
humor
cellular
respons
coadminist
vaccin
antigen
understand
mechan
tnfchp
nanoparticl
activ
innat
immun
conduct
gene
express
profil
nalt
cell
express
gene
relat
inflamm
immun
found
upregul
data
shown
base
result
focus
inflammatori
signal
molecul
perform
quantit
pcr
analys
enhanc
express
lp
bind
protein
found
tnfchp
nanoparticleadminist
mice
free
exogen
tnf
elicit
strong
earli
increas
express
inflammatori
signal
molecul
comparison
pattern
similar
extent
less
tnfchp
nanoparticl
figur
nanoparticl
might
effect
slow
releas
prolong
immunestimulatori
effect
taken
togeth
tnfchp
nanoparticl
seem
protract
activ
innat
immun
nanoparticl
might
prolong
stimulatori
effect
moder
therebi
provid
immuneenhanc
adjuv
effect
although
express
elicit
respons
ctb
adjuv
weakli
elicit
case
tnfchp
nanoparticl
chp
seem
minim
unfavor
effect
promot
benefici
activ
one
import
issu
relat
develop
nasal
vaccin
safeti
concern
potenti
dissemin
vaccin
antigen
central
nervou
system
cn
past
report
suggest
nasal
administr
ctb
reach
cn
accumul
olfactori
tissu
caus
bell
palsi
clinic
studi
probabl
due
product
use
ctb
human
prohibit
context
lower
express
level
might
benefici
safeti
featur
tnfchp
nanoparticl
although
chp
show
immuneenhanc
activ
increas
iga
express
inflammationrel
gene
show
certain
level
protect
lethal
influenza
viru
challeng
figur
easili
account
observ
like
pathway
mechan
involv
wait
clarifi
recent
onishi
et
al
report
anoth
type
saccharidebas
materi
form
nanoparticl
exhibit
adjuv
activ
elicit
strong
protect
effect
influenza
viru
mice
cynomolgu
macaqu
suggest
involv
tfh
cell
via
tbkdepend
pathway
find
may
shed
light
addit
mechan
play
nanoparticl
vaccin
adjuv
howev
mention
cytotox
vitro
probabl
abil
extract
cholesterol
cell
membran
tnfchp
nanoparticl
might
repres
prefer
altern
preliminari
safeti
studi
reveal
sever
toxic
find
result
exposur
tnfchp
nanoparticl
repeat
toxic
studi
slighttomoder
infus
infiltr
inflammatori
cell
observ
nasal
mucos
tissu
administr
site
respons
would
like
revers
time
enhanc
effect
tnfchp
nanoparticl
case
repeat
administr
induct
antigenspecif
antibodi
blood
confirm
tabl
even
care
histopatholog
examin
abnorm
find
brain
includ
olfactori
bulb
note
suggest
obviou
damag
cn
obviou
immunotox
detect
result
suggest
tnfchp
nanoparticl
rel
safe
nasal
vaccin
adjuv
result
studi
demonstr
tnfchp
nanoparticl
effect
vaccin
adjuv
administ
via
nasal
mucos
rout
moreov
abil
tnfchp
nanoparticl
stimul
compar
balanc
system
well
mucos
immun
respons
make
potenti
promis
vaccin
adjuv
induc
immun
infecti
pathogen
short
term
tnfchp
nanoparticl
may
provid
use
way
develop
new
nasal
influenza
vaccin
propos
combin
tnfchp
nanoparticl
nextgener
vaccin
platform
reli
cold
chain
offer
valuabl
altern
vaccin
varieti
set
